Clinicopathologic features of 358 patients with newly diagnosed APL
| Clinicopathologic parameters . | Value . |
|---|---|
| Patients, n | 358 |
| Period of diagnosis | |
| 2007-2012 | 158 (44.1) |
| 2013-2020 | 200 (55.9) |
| Sex | |
| Male | 173 (48.3) |
| Female | 185 (51.7) |
| Median age (range), y | 48 (1-97) |
| Age ≥50 y | 171 (47.8) |
| Age groups, y | |
| ≤17 | 29 (8.1) |
| 18-29 | 39 (10.9) |
| 30-39 | 44 (12.3) |
| 40-49 | 75 (20.9) |
| 50-59 | 77 (21.5) |
| 60-69 | 52 (14.5) |
| ≥70 | 42 (11.7) |
| Institution at initial presentation | |
| Regional hospitals | 306 (85.5) |
| QMH | 52 (14.5) |
| Hematologic features at first presentation | |
| Hemoglobin, median (range), g/dL | 8.4 (2.4-15.6) |
| Hemoglobin <8 g/dL | 155 (43.3) |
| Leucocyte count, median (range), ×109/L | 5.1 (0.1-337.6) |
| Leucocyte count ≥10 × 109/L | 129 (36) |
| Platelet count, median (range), ×109/L | 26 (2-481) |
| Platelet count, <40 × 109/L, | 239 (66.8) |
| PT, median (range), s* | 14.4 (9.9-120) |
| PT ≥16 s* | 99 (28.0) |
| Activated partial thromboplastin time, median (range), s* | 29.6 (19.7-180) |
| Activated partial thromboplastin time ≥40 s* | 12 (3.4) |
| Fibrinogen, median (range), g/L* | 1.5 (0-8.1) |
| Fibrinogen <1.5 g/L* | 163 (50.8) |
| Risk according to Sanz score | |
| Low | 84 (23) |
| Intermediate-high | 145 (41) |
| High | 129 (36) |
| Timing of ATRA administration | |
| 0-24 h of presentation | 287 (80.2) |
| >24 h after presentation | 71 (19.8) |
| Deaths within 30 d of presentation | |
| Total | 56 (15.6) |
| ICH | 25 (44.6) |
| Complications from APL-DS | 23 (41.1) |
| Infections | 8 (14.3) |
| Total deaths | 119 (33.2) |
| Median duration of follow-up (range), mo | 47 (0-166) |
| Clinicopathologic parameters . | Value . |
|---|---|
| Patients, n | 358 |
| Period of diagnosis | |
| 2007-2012 | 158 (44.1) |
| 2013-2020 | 200 (55.9) |
| Sex | |
| Male | 173 (48.3) |
| Female | 185 (51.7) |
| Median age (range), y | 48 (1-97) |
| Age ≥50 y | 171 (47.8) |
| Age groups, y | |
| ≤17 | 29 (8.1) |
| 18-29 | 39 (10.9) |
| 30-39 | 44 (12.3) |
| 40-49 | 75 (20.9) |
| 50-59 | 77 (21.5) |
| 60-69 | 52 (14.5) |
| ≥70 | 42 (11.7) |
| Institution at initial presentation | |
| Regional hospitals | 306 (85.5) |
| QMH | 52 (14.5) |
| Hematologic features at first presentation | |
| Hemoglobin, median (range), g/dL | 8.4 (2.4-15.6) |
| Hemoglobin <8 g/dL | 155 (43.3) |
| Leucocyte count, median (range), ×109/L | 5.1 (0.1-337.6) |
| Leucocyte count ≥10 × 109/L | 129 (36) |
| Platelet count, median (range), ×109/L | 26 (2-481) |
| Platelet count, <40 × 109/L, | 239 (66.8) |
| PT, median (range), s* | 14.4 (9.9-120) |
| PT ≥16 s* | 99 (28.0) |
| Activated partial thromboplastin time, median (range), s* | 29.6 (19.7-180) |
| Activated partial thromboplastin time ≥40 s* | 12 (3.4) |
| Fibrinogen, median (range), g/L* | 1.5 (0-8.1) |
| Fibrinogen <1.5 g/L* | 163 (50.8) |
| Risk according to Sanz score | |
| Low | 84 (23) |
| Intermediate-high | 145 (41) |
| High | 129 (36) |
| Timing of ATRA administration | |
| 0-24 h of presentation | 287 (80.2) |
| >24 h after presentation | 71 (19.8) |
| Deaths within 30 d of presentation | |
| Total | 56 (15.6) |
| ICH | 25 (44.6) |
| Complications from APL-DS | 23 (41.1) |
| Infections | 8 (14.3) |
| Total deaths | 119 (33.2) |
| Median duration of follow-up (range), mo | 47 (0-166) |
Data are number of patients (percentage of total group), unless otherwise indicated. Hematologic features at first presentation are shown as median levels in the patients tested with the number of patients tested on the following line.
Only 353 and 321 patients had clotting profile and fibrinogen level tested at presentation, respectively.